1. Home
  2. CVE vs INSM Comparison

CVE vs INSM Comparison

Compare CVE & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cenovus Energy Inc

CVE

Cenovus Energy Inc

HOLD

Current Price

$21.55

Market Cap

34.6B

Sector

Energy

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$150.87

Market Cap

31.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVE
INSM
Founded
2009
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6B
31.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CVE
INSM
Price
$21.55
$150.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
24
Target Price
$26.00
$192.27
AVG Volume (30 Days)
12.8M
2.3M
Earning Date
02-19-2026
02-19-2026
Dividend Yield
2.56%
N/A
EPS Growth
N/A
N/A
EPS
1.23
N/A
Revenue
$37,063,946,178.00
$447,022,000.00
Revenue This Year
N/A
$57.54
Revenue Next Year
N/A
$141.54
P/E Ratio
$17.83
N/A
Revenue Growth
N/A
30.34
52 Week Low
$10.23
$60.40
52 Week High
$22.20
$212.75

Technical Indicators

Market Signals
Indicator
CVE
INSM
Relative Strength Index (RSI) 64.76 40.19
Support Level $21.19 $142.99
Resistance Level $22.20 $152.19
Average True Range (ATR) 0.72 5.58
MACD 0.13 0.44
Stochastic Oscillator 80.49 38.75

Price Performance

Historical Comparison
CVE
INSM

About CVE Cenovus Energy Inc

Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: